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Tumor lysis syndrome (TLS) presenting in absence of chemotherapy is a rare occurrence. One of the true oncological emergencies,
it can lead to signiﬁcant morbidity and mortality. TLS is a phenomena usually associated with tumor cell death after treatment.
TheetiologyofthespontaneousTLSisnotwellunderstood,whichcomplicatesthediagnosis.TLSiswellknowntooncologistsbut
physicians outside of this specialty have little or no experience with this condition. Early recognition and treatment are the keys to
limiting the sequela of the condition. Spontaneous tumor lysis syndrome is rare but presents added risks to the patient because of
the potential for delayed diagnosis and no beneﬁt of pretreatment. Diagnosis may be further delayed because this may be the ﬁrst
symptom of underlying malignancy. Therefore, it is imperative that all clinicians are familiar with the syndrome to assure timely
recognition.
1.Introduction
Tumor lysis syndrome (TLS) is a phenomena usually
associated with tumor cell death after treatment. The
dying cells release vast amounts of electrolytes, protein
and nucleic acids into the extracellular space, which can
overwhelm homeostatic mechanisms. It may present with
multiple electrolyte abnormalities including hyperuricemia,
hyperphosphatemia, hypocalcemia and hyperkalemia and
can lead to multi-organ dysfunction, aﬀecting the kidneys,
heart, skeletal muscle and nervous system; TLS can be
fatal. TLS is considered one of the oncological emergencies.
SpontaneousTLS,occurringintheabsenceofchemotherapy,
is rare but might portend a worse prognosis. We present a
case of spontaneous TLS in a female with a later diagnosis of
large B-cell lymphoma.
2. Case Presentation
An 82-year-old woman presented to an outside institution
with several weeks of increasing dyspnea on exertion, fatigue
and weight loss. She was found to be anemic and transfused
RBC. Chest X-ray showed bilateral pulmonary nodules
(Figure 1) worrisome for metastatic disease. CT of the
pelvis and abdomen showed a 16cm adherent pelvic mass
and sizable masses in the gastro-hepatic ligament, adrenal
gland, and para-aortic area. (Figure 2) She was referred to
our institution. Vital signs revealed a blood pressure of
94/57, pulse 75/min, respiratory rate of 18/min, temperature
36.6◦C. Physical examination showed a fatigued appearing
woman. The abdomen was obese without palpable mass or
splenomegaly. No peripheral lymphadenopathy was palpa-
ble; there was 1+ lower extremity pitting edema. Laboratory
work showed serum urea nitrogen (BUN) 68 (normal 6–
21mg/dL), potassium 5.2 (normal 3.6–5.2mmol/L), sedi-
mentation rate 101 f(normal 0–21mm/1 hr), lactate dehy-
drogenase(LDH)478(normal122–222U/L)withadditional
results summarized in Table 1.
The patient was admitted for IVF hydration for pre-
sumed spontaneous TLS complicated by nonoliguric renal
failure. Obstructive uropathy and kidney inﬁltration by
t u m o rw e r ee x c l u d e db yC Ts c a n .S h ew a st r e a t e dw i t h
aggressive intravenous hydration and furosemide to main-
tain urinary output >200mL/h. Allopurinol was initi-
ated. Her laboratory values improved over the next 24
hours (Table 1). Other causes of renal failure such as2 Case Reports in Medicine
Table 1: Essential laboratory values during the ﬁrst 48 hours of treatment.
Time (hrs) Initial 2 4 7 12 24 48 Normal values
Calcium (Ionized) 4.41 4.09 4.25 4.01 4.25 4.25 4.85 4.80–5.70mg/dL
Phosphate 5.5 4.5 4.2 4.3 4.4 4.4 4.4 2.5–4.5mg/dL
Uric Acid 15.6 13.3 12.5 11.8 10.7 9.6 4.2 2.7–6.1mg/dL
Creatinine 1.8 1.3 1.2 1.1 1 0.9 0.9 0.6–1.1mg/dL
dehydration, contrast nephropathy, vasculitis, and cryoglob-
ulinemic glomerulonephritis were also considered but the
initial presentation as well as improvement with therapy
conﬁrmed the diagnosis of spontaneous TLS. Fine needle
biopsy of the abdominal mass revealed diﬀuse large b-
cell lymphoma, ultimately found to be stage IV-B by PET
imaging.
The patient subsequently underwent chemotherapy with
rituximab, doxorubicin, vincristine and prednisone (R-
CHOP). At the time of initiation of her chemotherapy her
uric acid was back to normal but because of the large tumor
burden and the history of spontaneous TLS the decision was
made to administer rasburicase one day prior to initiation
of chemotherapy to prevent occurrence of acute TLS. She
tolerated the treatment well with marked reduction in tumor
burden on follow up imaging. There was no recurrence
of TLS. Her course was complicated by the development
of asymptomatic pulmonary emboli but she completed 6
cycles of R-CHOP therapy with complete tumor remission.
Unfortunatelyoneyearlatershewasfoundtohavemetastatic
thyroid cancer and she passed away shortly after.
3. Discussion
TLS is a well-known phenomenon to the oncologist and it
most frequently occurs after the initiation of therapy for
various malignancies. The risk factors for developing acute
TLS after initiation of chemotherapy in all tumors are uric
acid level >7.5mg/dL at initiation of treatment, underlying
renal insuﬃciency, creatinine > 1.6mg/dL, hypercalcemia,
leukocytosis > 50,000m3, bulky disease, high LDH, high
tumor growth fraction [1, 2]. Non-Hodgkin’s lymphoma,
Burkitt’s lymphoma, other aggressive B-cell lymphomas,
acute lymphoblastic lymphoma and other hematological
malignancies are associated with higher risk of the occur-
rence of the acute TLS [3, 4]. It can also occur in solid
cancers [5]. Spontaneous TLS is a very rare occurrence,




TLS. The ﬁrst step in managing hyperuricemia is adequate
hydration. Patients should receive 2 to 4 times the daily
ﬂuid maintenance unless there are contraindications to
large ﬂuid volumes from other comorbidities. The increased
urine output should help with excretions of uric acid and
phosphate [9, 10]. The general consensus is that the urine
output should be above 100mL/m2/h [10, 11]. If the urine
output is still inadequate despite hydration, the use of
L
Figure 1: Chest X-ray showing multiple pulmonary nodules.
diuretics is then required. If urine output is still inadequate
despite hydration, diuretics should be used (loop diuretics
such as furosemide are ﬁrst-line; osmotic agents such as
mannitol have also been utilized). Recent expert guidelines
have recommended against alkalinization of urine due to
inadequate data on beneﬁts and potential complications
from the therapy [10, 11].
A recent addition to the armamentarium for treat-
ment of hyperuricemia in TLS is recombinant urate
oxidase/rasburicase. As seen in our case, urate oxidase
is eﬀective for prevention of TLS in high-risk patients
prior to initiation of therapy. It is contraindicated in
patients with Glucose-6-phosphate dehydrogenase (G6PD)
deﬁciency, therefore testing, including RBC NADPH, is
recommended before its use. Although in the US rasburicase
is only approved for use in children, it has shown eﬃcacy
in adults as well [12]. Allopurinol can also be used, but it
has major limitations. First, it only blocks the production
o fn e wu r i ca c i dw i t h o u ta n ye ﬀect on uric acid already
in circulation. It can also cause xanthine nephropathy. In
addition, because it is renally cleared, clinicians must use
allopurinol carefully in those with impaired renal function,
as is often encountered in this patient population.
In conjunction with above treatments, patients’ elec-
trolytes have to be monitored closely and corrected as
abnormalities present themselves. Although the incidence of
patients requiring dialysis has decreased, up to 5% of all
patients diagnosed with TLS still need the procedure [12].
Therefore, it is always important to involve renal specialist
early in the care.Case Reports in Medicine 3
Figure 2: CT of the pelvis with large pelvic mass.
The etiology of the spontaneous TLS is unclear at this
point. There are various hypotheses including increased
production of glucocorticoids and hyperthermia which lead
to increased tumor cell death [6, 13]. It is possible that
with the wide spectrum of tumors there can be multiple
causes of this syndrome. More research needs to be done
in order to better understand causes of spontaneous TLS.
Fortunately, spontaneous TLS is rare but there remains the
possibility of worse clinical outcomes because of the lack
of beneﬁt of pre-treatment. Also, because these patients
are often not under the care of oncologists, the syndrome
may go unrecognized, which delays appropriate treatment.
Therefore, it is imperative that general clinicians are able to
recognize the syndrome and initiate adequate care.
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